Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
European Respiratory Review : an Official Journal of the European Respiratory Society|August 20, 2021
Future concepts in bronchodilation for COPD: dual- versus monotherapyDave Singh, James F Donohue, Isabelle H Boucot, et al.
International Journal of Chronic Obstructive Pulmonary Disease|July 1, 2021
Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical TrialsNicola A Hanania, Scott Caveney, Tedi Soule, et al.
Respiratory Research|October 29, 2021
Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trialClaus F Vogelmeier, Paul W Jones, Edward M Kerwin, et al.
Advances in Therapy|August 4, 2021
Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX TrialLeif H Bjermer, Isabelle H Boucot, Claus F Vogelmeier, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 12, 2021
Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important ImprovementClaus F Vogelmeier, Ian P Naya, François Maltais, et al.
Therapeutic Advances in Respiratory Disease|May 29, 2020
Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trialEdward M Kerwin, Isabelle H Boucot, Claus F Vogelmeier, et al.
International Journal of Chronic Obstructive Pulmonary Disease|July 8, 2021
Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX TrialLeif Bjermer, Isabelle H Boucot, François Maltais, et al.
Chronic Respiratory Disease|October 6, 2023
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?Edward M Kerwin, Paul W Jones, Leif H Bjermer, et al.
Respiratory Medicine|July 8, 2022
Applying key learnings from the EMAX trial to clinical practice and future trial design in COPDFrançois Maltais, Claus F Vogelmeier, Edward M Kerwin, et al.
Therapeutic Advances in Respiratory Disease|November 10, 2020
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trialClaus F Vogelmeier, Edward M Kerwin, Leif H Bjermer, et al.
Pageof 2